Clinical trial results are expected by end of 2026 to guide dose selection for future ALS/MND and Parkinson’s studies. Credit ...

Today in the history of astronomy, one of the brightest and most famous scientific minds of the modern era is born.

In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

ALS is a rare and fatal disease that affects the nervous system, according to the Mayo Clinic. Also known as Lou Gehrig’s ...

Insmed outlines 2026 outlook, highlighting BRINSUPRI expansion, ARIKAYCE revenue guidance and multiple late-stage clinical ...

Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

A New York law grants patients the right to request aid in dying. But do the clinicians who guide them through that decision ...

Researchers at Qingdao University in China have developed a lightweight, self-powered eye-tracking system designed to assist ...

QRL-101, an oral small molecule being developed by QurAlis, was safe and reduced nerve-cell overactivity in ALS patients in ...

A finger-prick blood test that can be mailed to a lab may offer a simpler way to detect the brain changes linked to Alzheimer ...

As of Friday, January 09, Neumora Therapeutics, Inc.’s NMRA share price has surged by 9.01%, which has investors questioning ...